You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Merck
Moodys
Medtronic
Boehringer Ingelheim
Baxter
AstraZeneca

Last Updated: September 24, 2020

DrugPatentWatch Database Preview

Patent: 5,599,670

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,599,670
Title: .beta.-glucuronidase and glucuronide permease gene system
Abstract:The present invention relates to the .beta.-glucuronidase (GUS) gene fusion system, and to the cloning and characterization of the .beta.-glucuronidase and glucuronide permease genes of Escherichia coli. It is based on the surprising discovery that gene fusions comprising the .beta.-glucuronidase gene may be effectively expressed in a wide variety of organisms to produce active .beta.-glucuronidase enzyme. Because of the abundance and availability of useful substrates for .beta.-glucuronidase enzyme, GUS gene fusions may serve as a superior reporter gene system as well as an effective means of altering cellular phenotype. In conjunction with recombinant glucuronide permease, which may be used to render host cells permeable to .beta.-glucuronidase substrates, the GUS gene fusion system offers almost unlimited applications in the fields of plant and animal genetic engineering.
Inventor(s): Jefferson; Richard A. (Canberra, AU)
Assignee: Cambia Biosystems. L.L.C. (Canberra, AU)
Application Number:08/329,701
Patent Claims:see list of patent claims

Details for Patent 5,599,670

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial Cambia Biosystems. L.L.C. (Canberra, AU) 2014-02-04 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial Cambia Biosystems. L.L.C. (Canberra, AU) 2014-02-04 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial Cambia Biosystems. L.L.C. (Canberra, AU) 2014-02-04 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Boehringer Ingelheim
Dow
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.